Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632

NCT06320431 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT06320431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06320431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632
Lead sponsor
University of Calgary
Phase
Phase 3
Overall status
Recruiting
Start date
September 26, 2024
Completion date
December 31, 2030
Enrollment
4,000 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke ais, stroke acute, stroke, acute, stroke ischemic